Avidity Biosciences, Inc.(RNA)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,641 of 2,879 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
RNA Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Avidity Biosciences, Inc. (RNA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores RNA at 22.3/100 on a 32-signal composite quality model, placing it at rank #2,641 of 2,879 stocks — the bottom half of the AI-ranked universe. RNA scores in the top quartile across revenue growth (91.2). Areas of concern include institutional flow (0.2) and free cash flow (1.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 1.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q4 2025), Avidity Biosciences, Inc. reports quarterly revenue of $860.0K, net income of $-237.1M, free cash flow of $-175.3M. Top institutional holders of RNA by reported 13-F value include BlackRock,, SUSQUEHANNA INTERNATIONAL GROUP, LLP, RA CAPITAL MANAGEMENT, L.P., based on the most recent SEC filings. RNA trades on the Nasdaq exchange and files with the SEC under CIK 1599901. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RNA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Avidity Biosciences, Inc. directly from SEC EDGAR. Avidity Biosciences, Inc.'s 13F Pro composite quality score has ranged between 8 and 74 since 2021, currently 22.3 — a declining long-term trajectory across 56 quarterly and live scoring snapshots.
Revenue
Q4 2025
$860.0K
Net Income
Q4 2025
$-237.1M
Free Cash Flow
Q4 2025
$-175.3M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
+72.1% YoYNet Income
-112.4% YoYOperating Income
-96.9% YoYEPS (Diluted)
-72.0% YoYTotal Assets
+25.2% YoYOp. Cash Flow
-116.2% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $18.8M +72.1% | $10.9M +14.0% | $9.6M +3.6% | $9.2M -1.1% | $9.3M +37.4% | $6.8M |
| Net Income | $-684.6M -112.4% | $-322.3M -51.9% | $-212.2M -22.0% | $-174.0M -47.4% | $-118.0M -166.1% | $-44.4M |
| Operating Income | $-745.9M -96.9% | $-378.9M -60.8% | $-235.6M -31.7% | $-178.9M -51.6% | $-118.1M -166.6% | $-44.3M |
| EPS (Diluted) | $-4.97 -72.0% | $-2.89 +0.7% | $-2.91 +12.9% | $-3.34 -17.2% | $-2.85 -39.0% | $-2.05 |
| Total Assets | $1.96B +25.2% | $1.56B +148.8% | $628.6M -1.6% | $638.8M +49.4% | $427.6M +28.1% | $333.9M |
| Operating Cash Flow | $-650.4M -116.2% | $-300.9M -152.7% | $-119.1M +12.6% | $-136.3M -43.7% | $-94.8M -155.4% | $-37.1M |
Get alerted when RNA's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Avidity Biosciences, Inc. including:
Top Institutional Holders of RNA
BlackRock, Inc.
$16.1M1,205,291 shSUSQUEHANNA INTERNATIONAL GROUP, LLP
$13.6M1,018,800 shRA CAPITAL MANAGEMENT, L.P.
$11.6M864,102 shVANGUARD CAPITAL MANAGEMENT LLC
$8.4M626,869 shTIG Advisors, LLC
$8.1M607,552 shPentwater Capital Management LP
$8.1M602,649 shO'Connor Alternative Investments LLC
$7.7M578,011 shSessa Capital IM, L.P.
$7.4M551,391 shGOLDMAN SACHS GROUP INC
$4.7M349,950 shFARALLON CAPITAL MANAGEMENT LLC
$4.7M349,360 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $16.1M | 1,205,291 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $13.6M | 1,018,800 |
| RA CAPITAL MANAGEMENT, L.P. | $11.6M | 864,102 |
| VANGUARD CAPITAL MANAGEMENT LLC | $8.4M | 626,869 |
| TIG Advisors, LLC | $8.1M | 607,552 |
| Pentwater Capital Management LP | $8.1M | 602,649 |
| O'Connor Alternative Investments LLC | $7.7M | 578,011 |
| Sessa Capital IM, L.P. | $7.4M | 551,391 |
| GOLDMAN SACHS GROUP INC | $4.7M | 349,950 |
| FARALLON CAPITAL MANAGEMENT LLC | $4.7M | 349,360 |
More Healthcare Companies
View all Healthcare →Put RNA on your watchlist
Track score changes the day Avidity Biosciences, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is RNA a good stock to buy?
13F Pro's AI-powered analysis of Avidity Biosciences, Inc. (RNA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for RNA are available on the RNA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own RNA?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling RNA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Avidity Biosciences, Inc.'s investment landscape.